Cargando…
Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma
PURPOSE: CalliSpheres(®) microspheres (CSM) are the first drug-eluting beads (DEB) developed in China. This study aimed to compare treatment response, survival, and safety profiles between DEB transarterial chemoembolization (DEB-TACE) with CSM and conventional TACE (cTACE) in huge hepatocellular ca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814413/ https://www.ncbi.nlm.nih.gov/pubmed/35127501 http://dx.doi.org/10.3389/fonc.2021.793581 |
_version_ | 1784645050784808960 |
---|---|
author | Duan, Xuhua Liu, Juanfang Han, Xinwei Ren, Jianzhuang Li, Hao Li, Fengyao Ju, Shuguang |
author_facet | Duan, Xuhua Liu, Juanfang Han, Xinwei Ren, Jianzhuang Li, Hao Li, Fengyao Ju, Shuguang |
author_sort | Duan, Xuhua |
collection | PubMed |
description | PURPOSE: CalliSpheres(®) microspheres (CSM) are the first drug-eluting beads (DEB) developed in China. This study aimed to compare treatment response, survival, and safety profiles between DEB transarterial chemoembolization (DEB-TACE) with CSM and conventional TACE (cTACE) in huge hepatocellular carcinoma (HCC) patients. METHODS: A total of 71 patients with huge HCC who underwent DEB-TACE or cTACE were consecutively enrolled in this retrospective cohort study. Treatment response was assessed at first month (M1), third month (M3), and sixth month (M6) after TACE therapy; progression-free survival (PFS) and overall survival (OS) were evaluated; liver function indexes were recorded before TACE operation (M0), at first week (W1), M1 and M6 after TACE therapy; adverse events which occurred after TACE operation were recorded. RESULTS: DEB-TACE presented with higher objective response rate (60.0% vs. 29.7%, p < 0.05) and disease control rate (86.7% vs. 59.4%, p < 0.05) compared with cTACE at M3. Regarding survival profiles, PFS [median: 3.3 months (95% CI: 2.8–3.7) vs. 2.1 months (95% CI: 1.7–2.5)] as well as OS [median: 7.8 months (95% CI: 4.6–11.0) vs. 5.7 months (95% CI: 5.0–6.3)] were longer in DEB-TACE group compared with cTACE group (both p < 0.01). Multivariate Cox’s regression further illustrated that DEB-TACE vs. cTACE was an independent protective factor for PFS and OS (both p < 0.01). As for safety profiles, patients’ liver function injury was reduced in the DEB-TACE group compared with the cTACE group. The incidence of fever was lower, and CINV was less severe in the DEB-TACE group compared with the cTACE group (both p < 0.05), while no difference in occurrence of liver abscess, increase of ascites, or moderate pain between two groups was observed. CONCLUSION: DEB-TACE with CSM presents with better treatment response, survival profiles, as well as safety profiles compared with cTACE in treatment for huge HCC patients. |
format | Online Article Text |
id | pubmed-8814413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88144132022-02-05 Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma Duan, Xuhua Liu, Juanfang Han, Xinwei Ren, Jianzhuang Li, Hao Li, Fengyao Ju, Shuguang Front Oncol Oncology PURPOSE: CalliSpheres(®) microspheres (CSM) are the first drug-eluting beads (DEB) developed in China. This study aimed to compare treatment response, survival, and safety profiles between DEB transarterial chemoembolization (DEB-TACE) with CSM and conventional TACE (cTACE) in huge hepatocellular carcinoma (HCC) patients. METHODS: A total of 71 patients with huge HCC who underwent DEB-TACE or cTACE were consecutively enrolled in this retrospective cohort study. Treatment response was assessed at first month (M1), third month (M3), and sixth month (M6) after TACE therapy; progression-free survival (PFS) and overall survival (OS) were evaluated; liver function indexes were recorded before TACE operation (M0), at first week (W1), M1 and M6 after TACE therapy; adverse events which occurred after TACE operation were recorded. RESULTS: DEB-TACE presented with higher objective response rate (60.0% vs. 29.7%, p < 0.05) and disease control rate (86.7% vs. 59.4%, p < 0.05) compared with cTACE at M3. Regarding survival profiles, PFS [median: 3.3 months (95% CI: 2.8–3.7) vs. 2.1 months (95% CI: 1.7–2.5)] as well as OS [median: 7.8 months (95% CI: 4.6–11.0) vs. 5.7 months (95% CI: 5.0–6.3)] were longer in DEB-TACE group compared with cTACE group (both p < 0.01). Multivariate Cox’s regression further illustrated that DEB-TACE vs. cTACE was an independent protective factor for PFS and OS (both p < 0.01). As for safety profiles, patients’ liver function injury was reduced in the DEB-TACE group compared with the cTACE group. The incidence of fever was lower, and CINV was less severe in the DEB-TACE group compared with the cTACE group (both p < 0.05), while no difference in occurrence of liver abscess, increase of ascites, or moderate pain between two groups was observed. CONCLUSION: DEB-TACE with CSM presents with better treatment response, survival profiles, as well as safety profiles compared with cTACE in treatment for huge HCC patients. Frontiers Media S.A. 2022-01-21 /pmc/articles/PMC8814413/ /pubmed/35127501 http://dx.doi.org/10.3389/fonc.2021.793581 Text en Copyright © 2022 Duan, Liu, Han, Ren, Li, Li and Ju https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Duan, Xuhua Liu, Juanfang Han, Xinwei Ren, Jianzhuang Li, Hao Li, Fengyao Ju, Shuguang Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma |
title | Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma |
title_full | Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma |
title_fullStr | Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma |
title_full_unstemmed | Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma |
title_short | Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma |
title_sort | comparison of treatment response, survival profiles, as well as safety profiles between callispheres(®) microsphere transarterial chemoembolization and conventional transarterial chemoembolization in huge hepatocellular carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814413/ https://www.ncbi.nlm.nih.gov/pubmed/35127501 http://dx.doi.org/10.3389/fonc.2021.793581 |
work_keys_str_mv | AT duanxuhua comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma AT liujuanfang comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma AT hanxinwei comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma AT renjianzhuang comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma AT lihao comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma AT lifengyao comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma AT jushuguang comparisonoftreatmentresponsesurvivalprofilesaswellassafetyprofilesbetweencallispheresmicrospheretransarterialchemoembolizationandconventionaltransarterialchemoembolizationinhugehepatocellularcarcinoma |